Prof. Phil Newsome

Professor Newsome is Professor of Hepatology at King’s College London, Director of the Roger Williams Institute of Liver Studies and Director of the King’s Health Partners Centre for Translational Medicine. He runs the metabolic services at the Liver Unit at King’s College Hospital London, which includes a large multidisciplinary clinic for patients with non-alcoholic fatty liver disease (NAFLD). He was Chief Investigator on a randomized controlled trial of GLP-1 therapies in NAFLD published in the Lancet and the NEJM, is the Coordinating Investigator for several global NAFLD studies and is co-chair of the Phase 3 ESSENCE trial of semaglutide. He chaired the national guidelines for liver transplantation in NAFLD, is the topic advisor for the NICE Guideline Development Group for MASLD, led the UK multi-stakeholder guideline group on the management of abnormal liver blood tests and led on NAFLD for the recent EASL Lancet Liver Commission. He developed the FAST score for identifying patients with at-risk NASH and co-led the global nomenclature process that changed the name and definition of NAFLD to metabolic dysfunction-associated steatotic liver disease (MASLD).